Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor formulated as being a procedure for liver fibrosis and cirrhosis, was evaluated to assess the result of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Desk 4 Statistical evaluation of dose proportionality from the pharmacokinetic parameters of GB1211 https://harrisonv000hse2.wikitidings.com/user